桂林三金药业股份有限公司投资者关系活动记录表 | | 编号：2023012 | | --- | --- | | 投资者关系活动类别 | ■特定对象调研 ■分析师会议 | | | □媒体采访 □业绩说明会 | | | □新闻发布会 ■路演活动 | | | ■现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 国海证券 华安证券 方正证券 德邦证券 浙商证券等 68 | | | 家机构 82 人 | | | 桂林三金董秘 李春 | | | 桂林三金证代 朱烨 | | | 白帆生物管理团队 | | 时间 | 2023 年 05 月 09 日 | | 地点 | 桂林三金药业股份有限公司 | | 形式 | 线下交流 | | 5 | 月 9 日上午参加国海证券策略会 | | | 1、今年一季度业绩非常不错，主要是哪些品种发力，是否 | | | 可以展望一下全年的业绩？ | | | 一季度主要是西瓜霜的增长，从去年 12 月疫情爆发， | | | 销量增加，其次是三金片，两者占了销售总额的大半，剩 | | | 下一些是二三线产品。 | | | 接下来主要是依靠三金片发力，生产、销售政策逐渐向 ...

证券代码：002275 证券简称：桂林三金 桂林三金药业股份有限公司 桂林三金 2022 年度业绩说明会 投资者活动记录表 编号： 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 桂林三金2022年度业绩说明会采用网络远程方式进行，面向全体投资 者 时间 2023 年 5 月 8 日 15:00-17:00 地点 深圳证券交易所 "互动易平台 "http://irm.cninfo.com.cn "云访谈 "栏 目 公司接待人员 姓名 主持人：桂林三金 董事长：邹洵 副总裁兼财务负责人：谢元钢 董秘：李春 独立董事：何里文 投资者关系活动 主要内容介绍 1.请问邹董事长：我注意到三金公司的一线品种在各电商平台上价格较 乱，请问公司如何管控渠道价格？ 答：您好，互联网平台有其自身特点，多以打折促销引流，实现销售 数量和用户数量的增加。我公司产品在各大电商平台均有销售，部分 产品以不同品规、剂型开展线上销售工作。谢谢！ 2.请问邹董事长：2023 年一季度业绩怎么样 医疗终 ...

Financial Performance - The company's operating revenue for the current period reached ¥715,925,262.60, representing a 38.51% increase compared to the same period last year[1] - Net profit attributable to shareholders was ¥169,225,122.04, marking a 40.96% year-over-year growth[1] - The net profit after deducting non-recurring gains and losses was ¥163,783,894.84, up 42.86% from the previous year[1] - The basic earnings per share increased to ¥0.29, reflecting a 38.10% rise compared to the same period last year[1] - The weighted average return on equity improved to 5.84%, an increase of 2.95% from the previous year[1] - Total operating revenue for Q1 2023 reached ¥715,925,262.60, a significant increase from ¥516,891,871.81 in the same period last year, representing a growth of approximately 38.5%[21] - Net profit for Q1 2023 was ¥169,225,122.04, compared to ¥120,053,789.34 in the previous year, reflecting an increase of approximately 40.9%[24] - The total comprehensive income for the period was CNY 167,284,723.54, compared to CNY 119,558,821.49 in the previous period, representing an increase of approximately 39.9%[26] - Basic and diluted earnings per share increased to CNY 0.29 from CNY 0.21, reflecting a growth of 38.1%[26] Assets and Liabilities - Total assets at the end of the period were ¥4,121,500,711.51, a 3.95% increase from the end of the previous year[1] - The company's total assets increased to ¥4,121,500,711.51 from ¥3,964,926,749.15, marking a growth of about 3.9%[20] - Total liabilities decreased slightly to ¥1,129,072,575.33 from ¥1,151,594,802.44, a reduction of approximately 1.9%[20] - The total equity attributable to shareholders increased to ¥2,992,428,136.18 from ¥2,813,331,946.71, representing a growth of about 6.4%[20] Cash Flow - The company's cash flow from operating activities decreased by 67.67% to ¥54,238,486.87 compared to the same period last year[1] - Cash inflows from operating activities totaled CNY 706,984,153.47, up from CNY 638,327,757.79, indicating an increase of about 10.5%[27] - Cash outflows from operating activities amounted to CNY 652,745,666.60, compared to CNY 470,559,776.83 in the previous period, which is an increase of approximately 38.6%[27] - Net cash flow from operating activities was CNY 54,238,486.87, down from CNY 167,767,980.96, a decrease of about 67.6%[27] - Net cash flow from investing activities was CNY -68,739,822.89, slightly improved from CNY -73,360,724.97 in the previous period[30] - Net cash flow from financing activities increased significantly to CNY 115,975,857.88 from CNY 12,206,733.48, representing a growth of approximately 855.5%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,948, with the largest shareholder holding 62.07% of shares[9] - The top ten shareholders include both individual and institutional investors, with the largest shareholder being Guilin Sanjin Group[9] - The first phase of the employee stock ownership plan has a total of 6,147,975 shares unlocked, accounting for 1.05% of the total share capital[13] Government Subsidies - The company received government subsidies amounting to ¥7,910,246.54 during the current period[2] - The company received a government subsidy of 49 million RMB for a technology renovation project, expected to increase annual profit by 39.2 million RMB[13] Accounts Receivable and Inventory - Accounts receivable increased by 91.54% to ¥138,225,323.30, primarily due to increased sales and annual credit granted to distributors[4] - Accounts receivable increased to approximately 138.23 million RMB from 72.17 million RMB year-to-date[14] - The company’s inventory decreased to approximately 229.43 million RMB from 244.90 million RMB at the beginning of the year[14] Borrowings - Short-term borrowings rose by 102.77% to ¥283,900,256.67, mainly due to the renewal of loans that were due in the previous period[4] - The company’s long-term borrowings rose to ¥216,109,646.76 from ¥128,029,669.26, an increase of approximately 68.8%[20] Research and Development - Research and development expenses for the quarter were ¥73,161,443.46, compared to ¥70,056,723.81, showing an increase of about 3.0%[21]

Financial Performance - The company's total revenue for 2022 was ¥1,959,732,845.90, representing a 12.55% increase from ¥1,741,224,552.65 in 2021[22] - Net profit attributable to shareholders for 2022 was ¥329,526,519.63, a decrease of 4.13% compared to ¥343,718,942.74 in 2021[22] - The net profit after deducting non-recurring gains and losses was ¥222,383,595.89, down 14.62% from ¥260,467,690.06 in the previous year[22] - Basic earnings per share for 2022 was ¥0.56, a decrease of 6.67% compared to ¥0.60 in 2021[22] - Total assets at the end of 2022 were ¥3,964,926,749.15, down 3.20% from ¥4,095,868,127.50 at the end of 2021[22] - Net assets attributable to shareholders decreased by 0.93% to ¥2,813,331,946.71 from ¥2,839,817,165.26 in 2021[22] - Cash flow from operating activities increased by 28.87% to ¥528,666,938.97 from ¥410,241,541.70 in 2021[22] Product Development and Innovation - The company reported a total of 217 drug approvals, including 47 unique specialty products and 69 products listed in the National Essential Medicines List, indicating a strong product portfolio[47] - The company has 73 valid invention patents, including 1 US patent, showcasing its commitment to innovation and research[47] - The company completed 4 new drug projects and received 3 IND approvals for its biopharmaceutical pipeline, marking a significant step in its innovation journey[134] - The company is currently conducting Phase I clinical trials for a humanized anti-PD-L1 monoclonal antibody injection, aiming to enrich its biological drug pipeline[164] - The company has successfully launched new products and enhanced existing ones, focusing on both independent innovation and the development of traditional Chinese medicine[132] Market Position and Brand Value - The company has maintained a strong market position, being ranked among the top 50 Chinese traditional medicine companies and the top 100 pharmaceutical manufacturers in China[60] - The brand value of "SanJin" is estimated at CNY 11.229 billion, ranking it 4th in the pharmaceutical industry according to the World Brand Lab[60] - The market share of the "Guangxi Watermelon Frost" product in the oral ulcer traditional Chinese medicine market is 46.78%, while "SanJin Pian" holds a 43% market share in the urinary tract infection segment[121] - The company has received significant recognition for its products, including awards from the Guangxi Science and Technology Progress Award and inclusion in national guidelines for treating ischemic stroke[92] Strategic Goals and Future Outlook - The company aims to be a leading pharmaceutical manufacturing group in China, focusing on traditional Chinese medicine and biotechnology, with a strategy that emphasizes both core and auxiliary industries[46] - The Chinese pharmaceutical market is expected to grow significantly due to increasing health awareness and an aging population, providing a favorable outlook for the company's future[59] - The company aims to enhance its market presence through innovative product development and strategic partnerships in the healthcare sector[78] - The demand for traditional Chinese medicine products is expected to expand due to the aging population and increasing chronic disease rates, presenting new market opportunities[99] Risk Management - The company has identified risks including industry policy changes, product price declines, and increased market competition[13] - The company faces risks related to fluctuations in raw material prices, which could impact profitability[101] - The establishment of a national procurement office for traditional Chinese medicine may pose price reduction risks for the company's products[113] Operational Efficiency - The company has a comprehensive quality management system that has been recognized with multiple awards, including the National Quality Award nomination in 2018[125] - The company has a robust distribution network with 60 main distributors and 995 secondary distributors, ensuring effective market coverage[125] - The company has established an independent financial accounting department, ensuring compliance with national accounting laws and regulations[103] Research and Development - R&D investment as a percentage of operating revenue was 11.07%, down from 11.63%, a decrease of 0.56%[166] - The number of R&D personnel decreased to 253, a decline of 1.94% from 258 in the previous year[166] - R&D expenses rose by 7.20% to ¥217,036,372.78 compared to ¥202,449,905.05 in the previous year[182] Sales and Marketing - The pharmaceutical segment contributed CNY 1,856,101,015.73, accounting for 94.71% of total revenue, with a year-on-year growth of 12.28%[136] - The revenue from direct sales increased by 36.44% year-on-year, primarily due to growth in the Shanghai R&D and CDMO business[157] - The company's inventory for traditional Chinese medicine decreased by 39.35% year-on-year, driven by significant sales growth of key products[157]

桂林三金药业股份有限公司（以下简称"公司"）《2022年年度报告》已于 2023年4月26日经公司第八届董事会第二次会议审议通过，详情见2023年4月28 日《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）。为使广大投资者更加全面、深入地了解公司情 况，公司将于2023年5月8日召开2022年度业绩说明会，具体如下： 一、业绩说明会相关安排 1、时间：2023年5月8日（星期一）15:00-17:00。 2、召开方式：本次年度业绩说明会将采用网络远程文字交流的方式举行。 证券代码：002275 证券简称：桂林三金 公告编号：2023-016 桂林三金药业股份有限公司 关于召开2022年度业绩说明会并征集问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 3 、 参 与 方 式 ： 投 资 者 可 通 过 深 圳 证 券 交 易 所 "互动 易 " 平 台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与 ...

Group 1: Company Performance - The company's Xigua Frost series suffered significant losses during the pandemic, while the Sanjin Pian series maintained stable sales, becoming the main driver of the company's performance [1] - In 2022, the company experienced a recovery in Xigua Frost sales after the lifting of pandemic controls, with inventory replenishment completed by February 2023 [1] Group 2: Product Composition and Market Strategy - The company has a product composition of approximately 70% OTC (over-the-counter) drugs and 30% prescription drugs, with Sanjin Pian having a slightly higher hospital usage ratio compared to Xigua Frost [1] - The company views centralized procurement of traditional Chinese medicine as an opportunity rather than a challenge, especially for its unique products like Sanjin Pian, which are included in essential drug lists and have limited price reduction potential [1] Group 3: Research and Development - Baoshuan Bio is currently facing losses in R&D, but plans to continue investment in R&D and explore other business models, including financing and partnerships, without losing control [2] - The company expects to obtain 1-2 new clinical approvals in the current year, as part of its strategy to integrate resources and prepare for potential IPO [2]

Group 1: Company Strategy - The company's overall strategy focuses on traditional Chinese medicine as the core, with biopharmaceuticals and health industries as wings [1] - The traditional Chinese medicine segment includes over 40 proprietary products, categorized into first-line (e.g., Sanjin Pian, Xigua Shuang), second-line (e.g., Xuanvining, Naomaithai), and third-line products [1] Group 2: Revenue Composition - The majority of sales revenue comes from traditional Chinese medicine, with a smaller portion from chemical drugs and health products [1] - First-line products, such as the Sanjin Pian series and Xigua Shuang series, contribute significantly to revenue, while many third-line products are still in the market introduction phase [1] Group 3: OTC and Prescription Drug Ratio - The company has a ratio of approximately 70% OTC to 30% prescription drugs, with specific products like the Xigua Shuang series maintaining a 60/40 ratio [2] - The company views centralized procurement of traditional Chinese medicine as an opportunity rather than a challenge, as many products are unique and listed in essential drug directories [2] Group 4: R&D and Future Prospects - Baoshuan Biotech currently has 8 products with clinical approval and expects to obtain 1-2 new clinical approvals this year [2] - Baifang Biotech, positioned as the production base for biopharmaceuticals, aims to achieve breakeven this year while preparing for FDA certification [2]